AXT Inc. Earnings Call Signals Profitable Turn

AXT Inc ((AXTI)) has held its Q1 earnings call. Read on for the main highlights of the call.

Claim 55% Off TipRanks

AXT Inc.’s latest earnings call struck an optimistic tone, as management highlighted accelerating revenue growth, a surging indium phosphide backlog, and sharply improving margins that put profitability within reach. Still, executives repeatedly pointed to export-permit uncertainty, heavy capital spending, and manufacturing transitions as meaningful risks that investors should watch closely.

Revenue Growth

AXT reported Q1 2026 revenue of $26.9 million, up from $23.0 million in the prior period and $19.4 million a year earlier, marking roughly 17% sequential and 39% year-over-year growth. Management framed this acceleration as evidence that demand is scaling, particularly in optical and AI-related applications, even as permits and geopolitics remain a drag.

Indium Phosphide Strength & Mix

Indium phosphide was the star performer, generating $13.6 million in Q1 and representing just over half of total revenue, which significantly boosted both growth and margins. The backlog for indium phosphide substrates now exceeds $100 million, underscoring sustained demand from high-speed optical and data center markets and giving the company multi-quarter visibility.

Margin Expansion

Non-GAAP gross margin climbed to 29.9%, with GAAP gross margin close behind at 29.6%, a sharp improvement from 21.5% non-GAAP in the prior period. Compared with a negative non-GAAP gross margin of -6.1% a year ago, this swing signals a structural shift in profitability as higher-value products like indium phosphide gain share in the mix.

Narrowing Losses and Path to Profitability

Non-GAAP operating loss narrowed to just $0.55 million, down from $2.6 million in the prior quarter and roughly $9.6 million in the year-ago quarter, reflecting operating leverage on higher volumes. Non-GAAP net loss improved to $0.585 million, or $0.01 per share, and the company now expects both GAAP and non-GAAP profitability in Q2, with non-GAAP EPS guided to $0.06–$0.08.

Substantial Capital Raise

AXT completed a sizable $632.5 million capital raise aimed at funding Tongmei’s indium phosphide capacity build-out, advancing research and development for larger 6-inch wafers, and supporting working capital. Management presented this balance sheet reinforcement as a strategic move to secure share in fast-growing AI and optical markets, though it also raises pressure to execute.

Aggressive Capacity Expansion Plan

The company is running ahead of schedule on its plan to double indium phosphide capacity in 2026, targeting around $35 million in quarterly capacity by the end of that year. By 2027, AXT aims to reach $65–$70 million per quarter, implying annualized exit rates of roughly $140 million and then $280 million, positioning the business to capture potentially large upside if demand holds.

Raw Materials & Vertical Integration

Subsidiary Jinmei has begun refining high-purity indium, a critical raw material for indium phosphide substrates, giving AXT tighter control over supply and quality. Management views this vertical integration as a competitive differentiator that can support reliable deliveries for key customers while mitigating risk from third-party supply disruptions.

Geographic & Customer Momentum

Asia Pacific accounted for 78% of Q1 revenue, highlighting the region’s strategic importance to AXT’s growth profile, while the top five customers contributed about 32% with no single customer above 10%. The company cited expanding relationships with tier-one customers and hyperscalers, along with more long-term supply discussions, as signs of strengthening commercial momentum.

Export Permits and Geopolitical Uncertainty

Management repeatedly stressed that the timing and receipt of China export permits, including pending U.S.-related approvals, remain the biggest gating factor for revenue recognition. These permits are outside the company’s control and can materially swing quarterly results, creating a layer of geopolitical volatility over an otherwise robust demand picture.

Concentration in Asia Pacific

AXT’s heavy exposure to Asia Pacific, which drives more than three-quarters of revenue, brings concentration risk and ties performance closely to regional policy and macro conditions. While management is working on geographic diversification, they acknowledged that near-term results will remain heavily skewed toward China and broader Asia.

CapEx Intensity and Future Funding Needs

The capacity build-out comes with sizable capital expenditure requirements, with management estimating roughly $30–$40 million in 2026 and about $100 million in 2027 for an adjacent facility. Beyond that, a potential greenfield site could cost $220–$250 million, introducing execution and future funding risk even after the recent capital raise.

Working Capital & Inventory Build

Cash, cash equivalents, and investments declined by $5.1 million to $123 million in Q1, while net inventory rose by about $8.5 million to $90.2 million as AXT prepared for higher output. This inventory build signals heavier working capital absorption as the firm scales, which could pressure cash flow if permit delays or demand shifts emerge.

Dependence on Export Licenses for Gallium Arsenide

Demand for gallium arsenide substrates exists in areas such as industrial robotics, RF components, and data center laser applications, offering a potential growth vector. However, management emphasized that expansion in this segment is constrained by export license approvals, which were limited in Q1 and remain a bottleneck for capturing available opportunities.

Legacy Losses and Near-Term Profitability Uncertainty

Despite considerable improvement, AXT still posted a GAAP net loss of $1.6 million in Q1, underlining that it has yet to deliver a sustained multi-quarter profit track record. Future profitability will depend on permit timing, maintaining a favorable revenue mix, and continuing to improve manufacturing efficiency at higher volumes.

Product Transition & Manufacturing Complexity

The compound semiconductor market is gradually shifting from 3-inch to 4-inch and eventually 6-inch wafers, and AXT’s backlog is still weighted about four-to-one toward 3-inch today. Managing this transition, including ramping 6-inch production and shifting from sulfur-doped to indium-doped processes, adds technical and qualification risks that must be navigated carefully.

Listing/IPO Uncertainty

Plans to list Tongmei on China’s STAR Market remain in progress but are subject to evolving geopolitical and regulatory dynamics, leaving both timing and outcome uncertain. Management portrayed the potential listing as strategically important, yet conceded that external factors could reshape or delay this path.

Guidance and Forward-Looking Outlook

Looking ahead to Q2, management guided to sequential revenue growth driven by what is expected to be the company’s largest indium phosphide quarter ever, supported by a backlog above $100 million and about $34 million already cleared or not needing permits. They forecast achieving profitability, with non-GAAP net income of $0.06–$0.08 per share and GAAP net income of $0.05–$0.07, while cautioning that export permits could drive significant upside or downside.

AXT’s earnings call painted a picture of a company at an inflection point, combining strong demand and margin recovery with heavy investment and geopolitical risk. For investors, the story hinges on whether management can convert its large backlog and new capacity into sustained, permit-cleared revenue while mastering complex product transitions and maintaining financial discipline.